Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_4
3
50%
Ph phase_3
1
17%
Ph not_applicable
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
3(50.0%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 43 (50.0%)
N/A1 (16.7%)

Trials by Status

terminated117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_4

Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)

NCT02051413
completedphase_3

Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

NCT01571453
completednot_applicable

Improving Retention of Hispanics Receiving Antidepressant Therapy

NCT00057642
terminatedphase_2

Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder

NCT00766870
completedphase_4

Duloxetine vs. Active Comparator for the Treatment of Depression

NCT00067912
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02051413Phase 4

Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)

Completed
NCT01571453Phase 3

Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

Completed
NCT00057642Not Applicable

Improving Retention of Hispanics Receiving Antidepressant Therapy

Completed
NCT00766870Phase 2

Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder

Terminated
NCT00067912Phase 4

Duloxetine vs. Active Comparator for the Treatment of Depression

Completed
NCT00071695Phase 4

Duloxetine vs. Active Comparator in the Treatment of Patients With Depression

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6